Nabriva Therapeutics plc
Edit

Nabriva Therapeutics plc

https://www.nabriva.com/
Last activity: 26.05.2021
Tags:BioTechCorporateDevelopmentHomeLearnLifeMedtechProductResearch
Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta (lefamulin), recently approved by the FDA for both Oral and IV use and CONTEPO (fosfomycin) for injection, we submitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA. Nabriva is a commercial-stage biopharmaceutical company with locations in the United States (King of Prussia, PA, San Diego, CA), Austria (Vienna), and Ireland (Dublin), home of our corporate headquarters.
Mentions
11
Location: Ireland, Dublin
Employees: 51-200
Total raised: $120M
Founded date: 2006

Investors 8

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
07.04.2015Series B$120M-medcitynew...

Mentions in press and media 11

DateTitleDescriptionSource
26.05.2021Sinovant Sciences and Nabriva Therapeutics Announce Positive...- Lefamulin was shown to be non-inferior to moxifloxacin, with 76.8% of lefamulin-treated patients m...en.prnasia...
26.04.2021Vienna: Europe’s underestimated innovation hotspotAustria ~ Company: With almost 200 000 highly-educated and multi-linguistic students, out of which...therecursi...
20.12.2019Nabriva Therapeutics Announces $20 Million Registered Direct...-orbimed.co...
21.02.2017Ally Bridge Group Expands European Life Science Portfolio wi...HONG KONG and ZUG, Switzerland, Feb. 21, 2017 /PRNewswire/ — Ally Bridge Group (“ABG”), a leading gl...ally-bridg...
01.09.2016Zavante Therapeutics Secures $10 Million LoanZavante Therapeutics, a San Diego startup launched by biotech veterans last fall, has secured a $10 ...sdbj.com/n...
30.03.2016Zavante raises $45M to bring antibiotic fosfomycin to U.S.However, there’s nothing like fosfomycin on the U.S. market, CEO Ted Schroeder said in a phone inter...medcitynew...
30.03.2016Zavante Therapeutics Closes $45 Million Series A Financing I...SAN DIEGO, March 30, 2016 /PRNewswire/ — Zavante Therapeutics, Inc., a privately held, late clinical...aislingcap...
08.04.2015Nabriva Therapeutics raises $120M for drugs that attack anti...“We believe Nabriva is one of a few development stage companies with a truly novel antibiotic produc...medcitynew...
07.04.2015Nabriva Therapeutics Completes $120M Series B FinancingNabriva Therapeutics AG, a Vienna, Austria- and Philadelphia, PA-based biotechnology company focused...finsmes.co...
28.10.2009Austrian Nabriva Therapeutics Raises €15M in Equity Financin...Nabriva Therapeutics, a Vienna, Austria-baseed biotechnology company focused on developing a new cla...finsmes.co...
Show more